ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase by Tomar, Sunil et al.
lable at ScienceDirect
Cancer Letters 414 (2018) 190e204Contents lists avaiCancer Letters
journal homepage: www.elsevier .com/locate/canletOriginal ArticleETS1 induction by the microenvironment promotes ovarian cancer
metastasis through focal adhesion kinase
Sunil Tomar a, 1, Joshua P. Plotnik a, 1, James Haley a, 1, Joshua Scantland a,
Subramanyam Dasari a, Zahir Sheikh a, Robert Emerson b, Dean Lenz c,
Peter C. Hollenhorst a, d, e, Anirban K. Mitra a, d, f, *
a Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, United States
b Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, United States
c Urology, IU Health Southern Indiana Physicians, Bloomington, IN, United States
d Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, United States
e Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, United States
f Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United Statesa r t i c l e i n f o
Article history:
Received 18 August 2017
Received in revised form
23 October 2017
Accepted 11 November 2017
Keywords:
Ovarian cancer
Metastasis
Microenvironment
ETS1
FAK
OmentumAbbreviations: OC, ovarian cancer; TF, Transcriptio
kinase; MAP kinase, Mitogen activated protein kin
mesothelial cells.
* Corresponding author. 915 E. 3rd Street, Myers
47405, United States.
E-mail address: anmitra@indiana.edu (A.K. Mitra)
1 Authors have contributed equally.
https://doi.org/10.1016/j.canlet.2017.11.012
0304-3835/© 2017 The Author(s). Published by Elseviea b s t r a c t
Metastatic colonization involves paracrine/juxtacrine interactions with the microenvironment inducing
an adaptive response through transcriptional regulation. However, the identities of transcription factors
(TFs) induced by the metastatic microenvironment in ovarian cancer (OC) and their mechanism of action
is poorly understood. Using an organotypic 3D culture model recapitulating the early events of metas-
tasis, we identified ETS1 as the most upregulated member of the ETS family of TFs in metastasizing OC
cells as they interacted with the microenvironment. ETS1 was regulated by p44/42 MAP kinase signaling
activated in the OC cells interacting with mesothelial cells at the metastatic site. Human OC tumors had
increased expression of ETS1, which predicted poor prognosis. ETS1 regulated OC metastasis both in vitro
and in mouse xenografts. A combination of ChIP-seq and RNA-seq analysis and functional rescue ex-
periments revealed FAK as the key transcriptional target and downstream effector of ETS1. Taken
together, our results indicate that ETS1 is an essential transcription factor induced in OC cells by the
microenvironment, which promotes metastatic colonization though the transcriptional upregulation of
its target FAK.
© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ovarian cancer (OC) is the deadliest gynecologic malignancy
and fifth leading cause for cancer related deaths among women
in USA [1]. At the time of diagnosis, the disease has already
spread beyond the primary tumor inmost patients and this is the
main cause of OC related complications and morbidity [2,3].
However, our understanding of the regulation of the differentn factor; FAK, Focal adhesion
ase; HPMC, Human primary
Hall 200C, Bloomington, IN
.
r B.V. This is an open access article usteps of metastasis remains limited [4]. OC cells typically
metastasize to mesothelium-covered peritoneal organs, and
favorable interactions with the mesothelial cells and the un-
derlying basement membrane are essential for successful colo-
nization of the omentum, peritoneum, intestine, liver and other
sites [5,6]. While it is widely accepted that colonization of the
distant metastatic site is the rate-limiting step of metastasis [7,8],
not much is known about the underlying mechanisms that
regulate this process. This knowledge is limited due to the lack of
appropriate experimental models to specifically investigate this
key step. However, of late, some groups have devised in vitro 3D
culture models to mimic the early steps of colonization [9]. Such
models have yielded new insights into the process of
colonization.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of the metastatic site are critical for metastasis. The microenvi-
ronment of the metastasis site can influence the gene expression
patterns of the cancer cells determining their ability to establish
metastatic colonies [8]. Therefore, the initial interaction of OC
cells with mesothelial cells, the underlying basement membrane
and fibroblasts plays a crucial role in successful metastasis [10]. A
greater understanding of the underlying mechanism of regula-
tion of gene expression through signals from the microenvi-
ronment is essential to target metastasis. Transcription factors
(TFs) play a major role in regulation of gene expression and
several important TF families have been implicated in OC
[11e14]. In particular, the ETS family of TFs has been shown to
promote cellular migration and invasion through the activation
of genes such as matrix metalloproteases [15,16]. ETS1 regulates
awide variety of pro-tumorigenic effects [17] and is reported as a
marker of poor survival in OC and is associated with the clinical
stage and grade of the tumor [18,19]. However, the identity of the
ETS factors that mediate OC metastatic colonization, and the role
of the tumor microenvironment in this function are unclear.
Using an in vitro organotypic 3D culture model of the
omentum [20] which physiologically replicates the early steps of
metastatic colonization of OC, we have studied the potential
deregulation of oncogenic ETS transcription factors in OC cells as
a result of the cross-talk with the microenvironment. We report
the upregulation of ETS1 as a key event, which enhances the OC
cells' ability to metastasize both in vitro and in vivo. Moreover, by
genomic profiling of ETS1 binding sites, transcriptomic and
functional analyses, ETS1 was found to manifest its effects
through the transcriptional upregulation of focal adhesion ki-
nase (FAK).2. Materials and methods
2.1. Reagents
Trypsin, Dulbecco's Modified Eagle Medium (DMEM), MEM
vitamins, MEM nonessential amino acids and Penicillin-
Streptomycin were purchased from Media Tech (Manassas, VA).
TaqMan gene expression assay for ETS1 was obtained from
Applied Biosystems (Foster City, CA). Silencer™ Select ETS1
siRNA, FAK siRNA and scrambled negative control were from
Ambion (Austin, TX). Giemsa stain (Catalog # GS500) and crystal
violet (Catalog #C0775) were obtained from Sigma Aldrich.
Thiazolyl blue tetrazolium bromide was from Acros Organics
(Catalog # 298-93-1) and 4% paraformaldehyde solution was
purchased from Fisher Scientific (NC9245948).2.2. Cell lines
The OC cell lines HeyA8, OVCAR5 and OVCAR8 were obtained
from Ernst Lengyel, University of Chicago. Kuramochi cells were
obtained from Japanese Collection of Research Bioresources and
OVCAR4 from Joanna Burdette, University of Illinois at Chicago.
All cell lines were grown in DMEM with 10% FBS along with 1%
MEM vitamins, MEM nonessential amino acids and Penicillin-
Streptomycin. Idexx BioResearch's (Columbia, MO) validation
services for genetic validation of cell lines using CellCheck 16 (16Marker STR Profile and Inter-species Contamination Test) and
mycoplasma testing (Stat-Myco) was used to test all cell lines.2.3. Isolation and culture of primary cells and assembly of the 3D
culture
Omentum was obtained from female patients undergoing
surgery for benign conditions in the Indiana University Heath
Bloomington Hospital were used to isolate primary human
mesothelial cells (HPMC) and normal omental fibroblasts (NOF)
as described previously [20]. The primary cells were cultured in
DMEM with 10% FBS and were used to assemble the 3D omental
cultures as described previously [20]. Briefly, 360,000 NOFs with
91 mg of Collagen Type I (Rat tail, BD Cat#354236) were first
seeded in 10 cm dishes and 3.6 106 HPMCs were seeded on top
following attachment, to form a confluent monolayer. The 3D
culture was allowed to grow for 24 h to enable secretion of
growth factors and ECMs by the cells and subsequently used for
experiments to investigate the initial events of colonization. OC
cells (1  106) expressing GFP or labeled with cell tracker green
(Molecular Probes Cat# C2925) were seeded on the 3D culture
and allowed to grow for 2 days. The cancer cells were isolated by
fluorescence activated cell sorting (FACS) and used for RNA/
protein isolation. To set up the 3D culture in transwell inserts or
6 well plates, the number of cells and the amount of collagen
were proportionately reduced according to the growth surface
area. The Institutional Regulatory Board of Indiana University
approved this research and informed consent was obtained from
all patients.2.4. Real-time PCR
RNA was isolated from the cells using miRNeasy Kit (Qiagen
Catalog # 217004) and 0.5 mg RNA was used for reverse tran-
scription using Applied Biosystems High Capacity Reverse
Transcription Kit (Catalog # 4368813) on a Veriti 96-well ther-
mal cycler (Applied Biosystems). Quantitative real-time PCR
(qPCR) for ETS1, BCL2L12, SFN, ZNF114, EHD1, PTK2, CDH1, ZEB2
and FN1 expression was performed using TaqMan gene expres-
sion assay kit according to the manufacturer's protocol using
Roche LightCycler 96 system. GAPDHwas used as an endogenous
control. ETS family member real-time qPCR was carried out as
described previously [21]. The list of primers used is provided in
Supplementary Fig. 1.2.5. OC tissue microarray (TMA)
AnOC TMA assembled in the Indiana University Simon Cancer
Center consisting of formalin fixed paraffin embedded cores
from 23 ovarian tumors and 6 normal fallopian tubes was stained
for ETS1 with anti-ETS1 antibody (Aviva Systems Biology Catalog
#: P100604_T100) by the Indiana University School of Medi-
cine's Pathology and Laboratory Medicine core facility. The ETS1
nuclear expression was scored by a pathologist using a scale of
0 none, 1 weak, 2 moderate and 3 strong.
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OC cells were transiently transfected with 30 nM ETS1, PTK2
or scrambled control siRNA using TransIT-X2 (Mirus Bio Cat#
MIR 6000) following the manufacturer's protocol. For plasmid
transfections, 2e3 mg plasmid was transfected using FuGENE HD
(Promega Cat# E2311) or TransIT-2020 (Mirus Bio Cat# MIR
5400) as per the manufacturer's protocol. The cells were used for
experiments 48 h after transfection or as indicated.
2.7. Migration
Transwell migration assays were conducted using 8 mm pore
size inserts (BD, Falcon) as described previously [22]. OC cells
were seeded in the upper chamber in 500 ml DMEM and allowed
to migrate for 3e6 h at 37 C. DMEM with 10% FBS was used as a
chemoattractant in the lower chamber. Cells were fixed in 4%
paraformaldehyde and imaged (5 fields/insert) using an EVOS FL
Auto microscope (Life Technologies).
2.8. Proliferation
Proliferation assay was performed as described previously
[22]. Briefly, OC cells were seeded in 96-well plates in 8 repli-
cates (2000 cells/well) and allowed to grow for 5 days. On the
fifth day MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) Assay was conducted to mea-
sure proliferation of the OC cells. The absorbance was measured
at 560 nm and adjusted for background absorbance at 670 nm
using a SynergyH1 plate reader (BioTek).
2.9. Colony formation
Colony formation assay was performed as described previ-
ously [22]. Briefly, OC cells were seeded in 6 well plates
(1000 cells/well) and allowed to form colonies. Once visible
colonies were formed, they were fixed with 4% para-
formaldehyde and stained with 0.005% crystal violet and were
imaged using a Syngene G:Box imaging system and the number
of colonies/well were counted.
2.10. Invasion through 3D culture
Cellular invasion through the surface of the omentum was
assayed in vitro by first assembling the 3D culture on 8 mm pore
size Fluoroblock transwell inserts in 24 well plates. GFP-
expressing OvCa cells were then seeded on the 3D culture in
the transwell insert in 200 ml serum-free DMEM. DMEM with
10% FBS served as a chemoattractant in the lower chamber. CellsFig. 1. ETS1 is upregulated in OC. (A) Left: The orthotopic in vitro omental 3D culture mode
seeded on the 3D culture and allowed to grow for 2 days. The OC cells were then isolated us
factors by qPCR. Right: An image of GFP expressing OC cells growing on the 3D culture. (B) q
culture and data is expressed as fold change compared to control cells seeded on normal cel
standard deviations from 3 independent experiments. *p < 0.01, Students t-test (C) An OC TM
pathologist scored the nuclear ETS1 expression. The ETS1 expression in the OC tumors and
shown above. *p < 0.01, Students t-test. (D) Kaplan-Meier plot depicting the 5-year survi
analyzed using KM-plotter. The number of patients in the dataset were 655 and p ¼ 0.00043.
Relative ETS1 expression (log2) in TCGA ovarian serous adenocarcinoma patients (n ¼ 41
Browser. P-value determined by student's T-test. (F) qPCR for CDH1 (E-cadherin), ZEB2 and
on 3D culture and compared to controls grown on normal culture dishes. *p < 0.01, Studenwere allowed to invade for 16 h and then were fixed with 4%
paraformaldehyde. The fluorescent cancer cells that had invaded
were imaged (5 fields/insert) using an EVOS FL Auto microscope
(Life Technologies).
2.11. Colony formation on 3D culture
3D culture was set up in 6 well plates as described above and
OC cells expressing GFP were seeded in the plates (1000 cells/
well) and allowed to form colonies on the 3D culture. The green
fluorescent colonies were imaged using a Syngene G:Box imag-
ing system and the number of colonies/well were counted.
2.12. Generation of CRISPR/Cas9 ETS1 knockout cell lines
ETS1 KO cell lines were generated using LentiCRISPRv2
plasmid (Zhang, Addgene # 52961). Guide RNA's (gRNA) were
generated using algorithms found at crispr.mit.edu and can be
found in Supplementary Fig. 1 gRNA's were annealed and cloned
into the Cas9 backbone [23] and lentiviral particles were pro-
duced. After production, cells were transduced with virus and
selected with puromycin (5 mg/mL) was added at 24hr. Stably
transfected cells were counted and diluted to a concentration of
1 cell/200mL. In a 96-well plate, 100 mL of diluted cells were
plated and allowed to grow to confluence. Wells containing cells
were expanded into 24-well, then into 6-well tissue culture
plates. Once near confluency, single colonies were tested for
knockout efficiency via protein immunoblotting. Identification of
CRISPR/Cas9 generated indels were accomplished via gDNA PCR
and sequencing individual clones ligated into pet19 (NEB)
(Supplementary Fig. 2).
2.13. Mouse xenograft model of OvCa metastasis
The mouse xenograft model of OC metastasis was used as
described previously [10]. Briefly, 6 weeks old, female, athymic
nude mice were randomized into two groups (9 mice/group) and
were injected intraperitoneally (i.p.) with 1  106 HeyA8 cells
either wild type or with ETS1 knock out. Mice were euthanized
15 days post-injection and the tumors were surgically resected
and weighed.
2.14. Chromatin immunoprecipitation and sequencing
ChIP was carried out as previously described [24]. In short,
cells were cross-linked using 1% v/v Formaldehyde (Fisher Sci-
entific) for 15 min and quenched with 2 M Glycine for 5 min.
Isolated cells were lysed and sonicated for 3 min (30 s ON/OFF)
[Daigenode, Bioruptor Pico]. Nuclear lysate was rotated withl, which replicates the outer layers of the omentum. The GFP expressing OC cells were
ing FACS and their RNA was isolated to estimate the expression levels of oncogenic ETS
PCR was done to determine the expression of ETS factors in OVCAR8 cells seeded on 3D
l culture dishes. FLI1 and FEV had no expression in these cells. The error bars represent
A consisting of 23 OC tumors and 6 normal fallopian tubes was stained for ETS1 and a
normal fallopian tubes are plotted and representative images of the tissue cores are
val of ovarian cancer patients with high (red) or low (black) expression of ETS1 was
(E) ETS1 expression is upregulated in mesenchymal-like ovarian cancer patient tumors.
6) binned into epithelial-like and mesenchymal-like as determined by UCSC Cancer
FN1 (Fibronectin) were done in Kuramochi, OVCAR4, OVCAR8 and OVCAR5 cells grown
ts t-test.
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phenol/chloroform. Antibodies used in ChIP were from Santa
Cruz Biotechnology: anti-ETS1 (Santa Cruz Cat# SC-350). Library
preparation and data analysis was carried out as previously
described [25]. Data validation was done using ChIP-qPCR with
primers listed in Supplementary Fig. 1.2.15. RNA sequencing and analysis
Total RNA for three independent biological replicates was
isolated from HeyA8 cells transduced with lentiviral shRNA
knockdown vectors using the miRNeasy mini kit (Qiagen) ac-
cording to manufacturer's instructions. Sequencing libraries for
whole transcriptome analysis were generated using a modified
Illumina TruSeq sample preparation protocol as described pre-
viously [26]. The sequencing was performed by the Indiana
University Center for Genomics and Bioinformatics core facility
using an Illumina TruSeq.2.16. Immunofluorescence
The 3D culture was assembled on polyD-lysine coated glass
coverslips and OC cells expressing GFP or RFPwere seeded on the
3D culture or on the cover slips. At end point, cells were fixed
with 4% paraformaldehyde and permeabilized, blocked, and
probed with primary antibodies against ETS1, FAK, p-p44/42
MAPK and p44/42 MAPK (Santa Cruz Cat# SC-350, Cell Signaling
Cat# 3285, 4370 and 4695 respectively). Alexa Fluor 488 or 594
tagged secondary antibodies (Cell Signaling Cat# 44125 and
ThermoFisher Cat# A11039) were used for detection and the
nuclei were stained with Hoechst 33342 (ThermoFisher Cat#
H3570) and the coverslips were mounted with ProLong Gold
(ThermoFisher Cat# P36934) and imaged using a Leica SP8
confocal microscope.2.17. Immunoblotting
Immunoblotting was done as previously described [20].
Briefly, proteins were separated by 4e20% gradient SDS-PAGE
and transferred to nitrocellulose, probed with anti-ETS1 (Santa
Cruz Cat# SC-350), phospho-FAK (T397) or FAK antibody (Cell
Signaling Cat# 8556S and 3285S) and detected using a HRP-
linked anti-mouse or anti-rabbit IgG secondary antibody (Cell
Signaling, Cat# 7076, 7074). Actin (Sigma Cat# #G9295) was
probed as a loading control.Fig. 2. ETS1 inhibition decreases motility and clonogenic growth. (A) qPCR for ETS1 in
knocked down in HeyA8 cells, which were then compared with cells with shRNA against lu
using a transwell migration assay. Cells were seeded in transwell inserts with 8 mm pores and
cells were fixed, stained, imaged and counted (mean ± SD; 3 independent experiments). (C)
reduced matrigel and allowed to invade towards medium containing 10% FBS. Invaded cells w
HeyA8 cells with stable knock down of ETS1 were seeded in 6 well plates for colony forma
experiments). (E) The omental 3D culture was assembled in fluoroblock transwell inserts an
better mimic the initial invasion through the outer layers of the omentum. The invaded G
invaded GFP expressing HeyA8 cells are shown above the respective bars (mean ± SD; 3 inde
3D culture grown in 6 well plates to replicate early colonization of the omentum in vitro. The
colonies are shown above the bars (mean ± SD; 3 independent experiments). *p < 0.01, Stude
is referred to the web version of this article.)2.18. Treatment with U0126
The cells were treated with 10 mM U0126 (Cell Signaling Cat#
9903S) to inhibit p44/42 MAP kinase. Control cells were treated
with DMSO. Cells were lysed for immunoblotting or fixed for
imaging at indicated times.
2.19. TCGA data analysis for ETS1 and PTK2 expression
FPKM values for genes ETS1 (ENSG00000134954) and PTK2
(ENSG00000169398) were extracted from gene expression
dataset comprising of 379 ovarian cancer patient samples
downloaded from “Genomic Data Commons Data Portal”
(https://portal.gdc.cancer.gov/). Samples were ordered on ETS1
expression values and were grouped into three parts, each
containing a third of the samples (~127). Samples with ETS1
FPKM less than 2.89 went into first tertile and those with ETS1
FPKM greater than 4.85 went into the third tertile while those
in the middle went into second tertile. PTK2 FPKM values
for samples from first and third tertiles were plotted as box
plots.
2.20. Statistics
Data analysis was done by unpaired, two-tailed Student's t-
test assuming equal variance of the test and the control
populations.
3. Results
3.1. ETS1 is the most upregulated oncogenic ETS in OC metastatic
colonization
We have recapitulated the early events on metastatic colo-
nization using an organotypic 3D culture model mimicking the
outer layers of the human omentum [10] (Fig.1A). Briefly, normal
omental fibroblasts (NOFs) and human primary mesothelial cells
(HPMCs) were isolated from omentum samples obtained from
female donors undergoing abdominal surgeries for non-cancer
conditions. The NOFs were mixed with collagen 1 and seeded
first in the culture dishes. They were overlaid with a confluent
monolayer of HPMCs from the same patient. Together, this
mimics the outer mesothelium covering the omentum and the
underlying basement membrane. The GFP labeled ovarian cancer
cells (OVCAR8, KURAMOCHI and HeyA8) were seeded on the 3D
culture 24 h later. The ovarian cancer cells were isolated 2 daysa panel of OC cell lines to determine its baseline expression levels. ETS1 was stably
ciferase as controls in various assays. (B) The effect of knocking down ETS1 was tested
allowed to migrate towards the chemottractant (mediumwith 10% FBS). The migrated
ETS1 silenced HeyA8 cells were seeded in transwell inserts coated with growth factor
ere fixed, stained, imaged and quantified (mean ± SD; 3 independent experiments). (D)
tion assay. The colonies were fixed, stained and counted (mean ± SD; 3 independent
d the ETS1 silenced HeyA8GFP cells were allowed to invade through the 3D culture to
FP expressing cells were imaged, counted and plotted. Representative images of the
pendent experiments). (F) HeyA8GFP cells were seeded to form colonies on the omental
fluorescent green colonies formed were imaged and counted. Respective images of the
nts t-test. (For interpretation of the references to colour in this figure legend, the reader
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mRNA levels of various ETS factors previously implicated in
cellular migration and invasion (ETS1, ETS2, ETV1, ETV4, ETV5,
ERG, FLI1 and FEV) in these OC cells by qPCR. ETS1 was found to
be the most commonly upregulated among these ETS factors in
the OC cells seeded on the 3D culture (Fig. 1B and Supplementary
Fig. 3A). OC cells seeded on HPMCs alone also demonstrated a
similar increase in ETS1 expression (Supplementary Fig. 3B).
Therefore, we concluded that the interactions of the OC cells
with themesothelial cells were sufficient to trigger an increase in
ETS1 expression in the OC cells. Thereafter, we compared ETS1
expression levels in ovarian cancer patient tumors, which were
chemo-naïve to that of normal fallopian tubes since most high-
grade serous ovarian cancer originates from the fallopian tube
[27]. Immunohistochemical staining for ETS1 in an OC tissue
microarray revealed a significant increase in ETS1 expression in
ovarian tumors relative to normal fallopian tubes (Fig. 1C). An
analysis of the effect of ETS1 overexpression on prognosis in OC
patients was done using the KM-plotter database [28,29]. Over-
expression of ETS1 resulted in decreased 5-year survival of OC
patients (Fig. 1D) with the median survival being 36 months for
high ETS1 expression compared to 50.97 months for low ETS1
expression. No significant difference was noted for ETS2 and
ETV1 (Supplementary Fig. 4).
We next used the data from The Cancer Genome Atlas (TCGA)
[14] to test if ETS1 levels in tumors correlated with epithelial-
mesenchymal transition (EMT). Tumors were separated into
epithelial and mesenchymal groups based on EMT score [30] and
ETS1 expression levels were compared between groups. Tumors
with higher mesenchymal gene expression also had significantly
higher levels of ETS1 compared to ovarian tumors with a more
epithelial gene signature (Fig. 1E). Therefore, ETS1 potentially
regulates or is associated with a gene expression program that
correlates with an EMT phenotype. To confirm this in our system,
the expression of the epithelial marker E-cadherin (CDH1) and
the mesenchymal markers Zeb2 and fibronectin (FN1) was
analyzed by qPCR in Kuramochi, OVCAR4, OVCAR8 and OVCAR5
cells seeded on the 3D culture (Fig. 1F). The mesenchymal
markers were found to be markedly increased in the OC cells
upon interaction with the 3D culture while E-cadherin remained
unchanged in Kuramochi and OVCAR4 but increased slightly in
OVCAR8 and OVCAR5. This reflects the complex regulation of the
EMT phenotype and indicates that ETS1 may be one of many
regulators involved. Since a mesenchymal phenotype favors OC
metastasis to the omentum [31] we proceeded to investigate the
role ETS1 in OC metastasis.Fig. 3. ETS1 promotes OC metastasis. (A) ETS1 was transiently overexpressed in OVCAR5 c
ability to migrate was compared to vector control cells (EV). The migrated cells were image
bars (mean ± SD; 3 independent experiments). (B) The ability of ETS1 overexpressing He
assembled in fluoroblock transwell inserts were compared with vector control cells. The flu
invaded cells are shown above the respective bars (mean ± SD; 3 independent experimen
immunoblotting for ETS1 protein expression was done with the clones to confirm knockout.
and the invaded cells were imaged and quantified (mean ± SD; 3 independent experiments)
OC metastasis. HeyA8 cells with ETS1 knocked out (ETS1 KO) or wild type controls (WT) w
group). Mice were euthanized after 15 days and the tumors surgically removed and weigh
sentative images of tumor bearing mice are shown above respective groups. *p < 0.01, Stude
is referred to the web version of this article.)3.2. ETS1 plays an important role in metastasis
Having observed an increase in ETS1 expression in OC cells
interacting with mesothelial cells and that ETS1 overexpression
correlates with poor outcome in OC patients, we proceeded to
investigate the functional effects of ETS1 on OC cells. As the OC
cells attach to the mesothelium covering the omentum, they
need to invade and proliferate to establish the metastatic col-
onies so we tested motility, invasiveness and clonogenic growth.
In order to determine the OC cell lines to be used for silencing or
overexpressing ETS1, we profiled ETS1 expression levels in a
panel of OC cell lines (Fig. 2A). HeyA8 and OVCAR5 have high and
intermediate levels of expression of ETS1 and they perform very
robustly in functional assays [22] and were selected for the
subsequent experiments. Transient silencing of ETS1 in HeyA8
and OVCAR5 OC cells resulted in a decrease in their migration,
invasion and colony formation (Fig. 2 BeD and Supplementary
Fig. 5). To test the effect of ETS1 on OC metastasis in vitro, ETS1
was silenced in GFP expressing HeyA8 cells, which were then
allowed to invade through the omental 3D culture assembled in
fluoroblock transwell inserts. This effectively mimicked the
attachment and subsequent invasion of OC cells through the
outer layers of the omentum. The invaded GFP expressing cells
were imaged and counted. ETS1 knock down resulted in a
decrease in the ability of HeyA8 cells to invade through the 3D
culture (Fig. 2E). Similarly, ETS1 was silenced in GFP expressing
HeyA8 cells, which were allowed to colonize 3D omental cul-
tures assembled in 6well plates. The fluorescent colonies formed
were imaged and quantified. Knocking down ETS1 decreased
their ability to form colonies on the 3D culture (Fig. 2F). Silencing
was confirmed with qPCR and western blotting (Supplementary
Figs. 6A and B). Taken together, the above data indicated that
depleting the endogenous levels of ETS1 in OC cells resulted in a
decrease in their functions that are necessary for colonizing the
metastatic site like motility, invasiveness and growth. More
importantly, using the 3D organotypic culture, these decreased
functions were also recapitulated in OC cells undergoing early
metastatic events.
We next proceeded to test the functional effects of over-
expressing ETS1 in OC cells. Transient overexpression of ETS1 in
OVCAR5 OC cells resulted in an increase in their trans-well
migration (Fig. 3A). GFP expressing HeyA8 and OVCAR5 cells
were transiently transfected with an ETS1 overexpression vector
and were allowed to invade through 3D omental cultures
assembled in fluoroblock trans-well inserts. The fluorescent
invaded cells were imaged and quantified. Overexpression ofells (ETS1 OE) which were then seeded in transwell inserts with 8 mm pores and their
d and quantified. Representative images of migrated cells are shown above respective
yA8GFP (left) and OVCAR5 (Right) cells to invade through the 3D omentum culture
orescent green invaded cells were imaged and counted. Representative images of the
ts). (C) Top: ETS1 was knocked out in HeyA8 cells (ETS1 KO) using CRISPR/Cas9 and
Bottom: ETS1 KO HeyA8 cells were allowed to invade through the 3D omentum culture
. (D) Mouse xenograft model of OC metastasis was used to test the effect of ETS1 KO on
ere injected intraperitoneally in 6-week-old female athymic nude mice (n ¼ 9 mice/
ed. The tumor weight was plotted with the mean values indicated alongside. Repre-
nts t-test. (For interpretation of the references to colour in this figure legend, the reader
Fig. 4. Determination of transcriptional targets of ETS1 in OC. (A) Top: ChIP-seq data presented as a heat map of ETS1 enrichment at transcriptional start sites (TSS) genome wide,
as determined by NGSPlot. Bottom: Venn diagram of all overlapping bound regions (promoter and enhancer) between ETS1 in HEYA8 and OVCAR8 ovarian cancer cell lines. Number
in parenthesis indicated number of bound regions as expected by random chance, based on estimate of 125,000 possible regions of open chromatin. (B) Heat map of relative RPKM
values determined by RNA-seq differential expression analysis and created by cummeRbund (red ¼ low expression, green ¼ high expression). Top 50 genes activated by ETS1 and
repressed by ETS1 are shown along with three biological replicates. Z-score scale from 1 to 1 used to determine intensity of red/green colors in each sample. (C) ChIP-qPCR was
performed to validate ETS1 binding to the promoters of the top targets. (D) qPCR validation of the RNA-seq results for the top targets (mean ± SD; 3 independent experiments)
*p < 0.01 compared to respective control.
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Table 1
Most over-represented ontologies of 289 genes significantly changed upon ETS1
knockdown.
Ontology P-value
Regulation of cell migration 2.2  1011
Positive regulation of developmental process 1.1  108
Regulation of cell proliferation 1.6  108
Anatomical structure formation 1.6  107
Regulation of response to stimulus 2.9  107
S. Tomar et al. / Cancer Letters 414 (2018) 190e204 199ETS1 resulted in increased invasion through the 3D culture
(Fig. 3B). Overexpression was confirmed by western blotting
(Supplementary Fig. 7A). Having confirmed that ETS1 is func-
tionally relevant for OC metastasis in vitro, we next tested the
role of ETS1 in OC metastasis in vivo using a mouse xenograft
model of OC metastasis. ETS1 was knocked out in HeyA8 cells
(HeyA8 ETS1 KO) using CRISPR-Cas9 (Fig. 3C (top),
Supplementary Fig. 2) and the functional effects of its knockout
were confirmed with invasion through the 3D culture (Fig. 3C,
bottom). HeyA8 ETS1 KO or wild type control HeyA8 cells
(1  106 cells) were injected intraperitoneally in female athymic
nude mice (9 mice per group). Mice were euthanized 15 days
after injecting the cancer cells and the tumors were surgically
removed and weighed. Knocking out ETS1 resulted in a signifi-
cant decrease in metastatic tumors in the mice (Fig. 3D).
3.3. ETS1 drives OC metastasis phenotypes through its
transcriptional target PTK2
To identify direct targets of ETS1 that might be responsible for
its functional effects, ETS1 ChIP-seq was done in both HeyA8 and
OVCAR8 cells. Comparison of ETS1 binding across all promoter
regions in these two cell lines showed strikingly similar profiles
(Fig. 4A). In total, ETS1 bound 6431 regions in HeyA8 cells and
6267 regions in OVCAR8. Among them, 3483 regions were in
common, a greater than 10-fold enrichment over the random
prediction (Fig. 4A). These data indicate that the ETS1 cistrome is
conserved across multiple ovarian cancer cell lines. In a parallel
approach, ETS1 was stably knocked down in HeyA8 cells and the
gene expression levels in these cells were compared with the
vector control cells using mRNA-seq. 289 genes had significant
changes in gene expression (P < 0.01) (Supplemental Table S1).
Ontology analysis of these 289 genes revealed that the most
over-represented function was “Regulation of cell migration”
(Table 1), consistent with our finding in Fig. 2B, andwith the EMT
signature in OC TCGA data (Fig. 1E). Of the 289 genes that change
expression after ETS1 knockdown in HeyA8 cells, 97 had a
neighboring ETS1-bound region in HeyA8 cells, and 54 had the
same region bound by ETS1 in OVCAR8 cells (Supplementary
Table S1). From these 54 genes, we then selected the five
(excluding ETS1 itself) that decreased the most upon ETS1
knockdown for further analysis (Fig. 4B). ChIP enrichment and
decreased expression of these genes upon ETS1 knockdownwere
then validated by quantitative PCR (Fig. 4C and D).
Among these top five targets of ETS1 in ovarian cancer cells
was protein tyrosine kinase 2 (PTK2), which codes for focal
adhesion kinase (FAK), a protein involved in processes essential
for invasion and metastasis [32e34]. We and others have pre-
viously demonstrated the role of FAK in ovarian cancer metas-
tasis to the omentum [10,35e37]. To confirm the
downregulation of FAK at the protein level, immunoblotting was
done using protein lysates from ETS1 KO OC cells. We observed a
decrease in FAK protein expression in ETS1 KO cells (Fig. 5A).Immunofluorescence imaging of FAK in these cells indicated that
ETS1 was only involved in regulating the expression and not the
distribution of FAK (Fig. 5B). Thereafter, we tested if knocking
down FAK (Supplementary Fig. 7B) in OC cells could phenocopy
the functional effects of knocking down ETS1. Silencing FAK
resulted in decreased migration and proliferation (Fig. 5C and D).
This indicated that loss of FAK had similar effects on the OC cells
as the loss of ETS1. To confirm that FAK was functioning down-
stream of ETS1, a functional rescue experiment was performed.
FAK was overexpressed in ETS1 KO cells followed by migration
assay. As expected, the ETS1 KO cells decreased migration
compared to the WT cells and overexpression of FAK in the ETS1
KO cells reverted the migration levels back to the WT levels
(Fig. 5E). Similar effects were observed for colony formation
(Supplementary Fig. 8). These results implicate FAK as a down-
stream effector of ETS1 during ovarian cancer metastasis to the
omentum. We also analyzed the expression levels of ETS1 and
PTK2 in the ovarian cancer TCGA data and PTK2 expression was
significantly higher in tumors with high ETS1 expression
(Fig. 5F). To better understand the mechanism of transcriptional
regulation of PTK2 by ETS1, the ETS1 bound regions of the PTK2
promoter was analyzed in HeyA8 and OVCAR8 using our ChIP-
seq data showing common binding sites as well as cell type
specific binding (Fig. 5G).3.4. ETS1 expression is regulated by activation of MAP kinase
signaling induced by the microenvironment
We next attempted to identify themechanism of regulation of
ETS1 in the metastasizing OC cells when they interact with the
mesothelial cells. ETS1 has been reported to be phosphorylated
by p44/42 mitogen activated protein kinase (MAPK) at its T38
and S41 residues, which increases its activity by enhancing its
affinity for the co-activator CBP/p300 [38,39]. Since ETS1 can also
regulate its own transcription, this can potentially lead to
increased ETS1 expression. Therefore, we treated OC cells with
U0126, which inhibited p44/42 MAPK signaling (Supplementary
Fig. 9A) causing a decrease in ETS1 protein expression and
phosphorylation (Fig. 6A) as well as ETS1 mRNA levels
(Supplementary Fig. 9A). It also decreased FAK expression
(Supplementary Fig. 9A). We then tested the effect of inhibition
of p44/42 MAPK signaling in OC cells seeded on the 3D culture. A
significant decrease in ETS1 expression in the OC cells was
observed upon p44/42 MAPK inhibition in OC cells seeded on 3D
culture compared to controls (Fig. 6B). Moreover, increased
phosphorylation of p44/42 MAPK was observed in OC cells
seeded on the 3D culture compared to controls (Fig. 6C). How-
ever, the total p44/42 MAPK protein levels remained unaffected
by the interactions with the 3D culture (Supplementary Fig. 9C).
Thereafter, we proceeded to investigate the functional effects of
p44/42 MAPK inhibition on the ability of the OC cells to migrate.
Treatment with U0126 inhibited migration and mimicked the
effects of ETS1 knock down. However if the cells were trans-
fected with a constitutively active ETS1 (T38E or T38E and S41E)
(Supplementary Fig. 9B), it rescued the cells from the effects of
MAPK inhibition on migration (Fig. 6D). Taken together, this in-
dicates that the activation of p44/42 MAPK signaling in the OC
cells interacting with the mesothelial cells that cover the
omentum leads to the activation and overexpression of ETS1. The
ETS1 overexpression leads to increased FAK levels, which helps
the OC cells to invade into the omentum and form the metastatic
tumor (proposed model in Fig. 6E).
Fig. 5. FAK is the functional effector of ETS1 in OC. (A) Immunoblot for FAK in ETS1 knockout (ETS1 KO) HeyA8 cells compared to the wild type (WT) control. Quantification of FAK
expression normalized to actin is plotted below. (B) Immunofluorescence analysis of FAK (green) expression in ETS1 knockout (ETS1 KO) HeyA8 cells compared to the wild type
(WT) control. Nuclei are stained with Hoechst 33342. (C) Transwell migration assay was performed with OVCAR5 cells transiently transfected with FAK siRNA or scrambled control.
The migrated cells were imaged and quantified (mean ± SD; 3 independent experiments). (D) OVCAR5 cells were transfected with FAK siRNA or scrambled control and were used to
perform a proliferation assay (mean ± SD; 3 independent experiments). (E) FAK was transiently overexpressed in ETS1 knockout (ETS1 KO) or wild type (WT) HeyA8 cells and these
cells were subjected to transwell migration with medium containing 10% FBS serving as the chemottractant. Migrated cells were imaged and quantified (mean ± SD; 3 independent
experiments). (F) Plot comparing the expression of PTK2 in tumors segregated into 1st and 3rd tertiles on the basis of their ETS1 expression levels from the ovarian cancer TCGA
gene expression data (n ¼ 379). (G) ETS1 occupancy at the PTK2 promoter is plotted by -log binomial P-value from ChIP-seq data of HeyA8 and OVCAR8 OC cells. *p < 0.01 compared
to respective control. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 6. MAP kinase signaling induced by the microenvironment upregulates ETS1. (A) Left: HeyA8 or Kuramochi cells were treated with 10 mM U0126 or DMSO and cells were
lysed after 48 h of treatment. Immunoblotting for phosphorylated ETS1 (pETS1) and total ETS1 was performed using the lysates. Right: Quantification of the western blots for pETS1
and ETS1 normalized to actin for each cell is provided for the respective blots. (B) HeyA8GFP cells were seeded on the 3D omentum culture and treated with 10 mM U0126 or DMSO
for 48 h and then fixed and immunostained for ETS1 (red) and nuclei were stained with Hoechst 33342 to reveal the normal cells of the 3D culture. (C) HeyA8GFP cells were seeded
on the 3D omentum culture for 48 h and then fixed and immunostained for phosphorylated p44/42 MAPK (red) and nuclei were stained with Hoechst 33342. (D) HeyA8 cells were
transiently transfected with constitutively active ETS1 (ETS1 T38E or ETS1 T38E S41E) which were then treated with 10 mM U0126 or DMSO and used for transwell migration assay.
Error bars represent mean ± SD; 3 independent experiments. (E) Proposed model: Upon interactions with the mesothelial cells covering the omentum, MAPK pathway is activated
in the metastatic OC cells. This results in the activation and increased transcription of ETS1 which upregulates the transcription of its target PTK2. PTK2 codes for FAK, which
promotes the initial invasiveness and growth, needed for metastatic colonization. *p < 0.01 compared to respective control.
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The roles of the tumor microenvironment and the microen-
vironment of the metastatic site have increasingly come into
focus over the recent years as key determinants of successful
metastasis [40]. With the use of 3D culture models, we and
others have demonstrated the molecular mechanisms involved
in the cross-talk between cancer cells and themicroenvironment
during early metastatic colonization of OC to the omentum
[6,20,41e43]. However, little is known about pro-metastatic
gene expression changes induced by transcription factors acti-
vated via interaction with the metastatic microenvironment.
Using an organotypic 3D culture model that mimics the surface
layers of the omentum, we report here the upregulation of ETS1
as a result of interaction of the cancer cells with the mesothelial
cells that cover the omentum (Fig. 1). Analysis of published OC
patient datasets using KM-plotter showed an increased ETS1
expression led to poor prognosis in OC patients (Fig. 1). We also
found an increased ETS1 protein expression in TMAs of OC tu-
mors compared to normal fallopean tubes (Fig. 1). ETS1 was
found to be functionally important for metastatic colonization
in vitro as well as in mouse xenografts (Figs. 2 and 3). The key
transcriptional target was identified as PTK2which codes for FAK
and was found to be responsible for the increased invasiveness/
motility and growth (Fig. 5). ETS1 was found to be regulated in
the OC cells by the activation of MAP kinase signaling triggered
by their interactions with the mesothelium covering the meta-
static site (Fig. 6).
Increased ETS1 mRNA expression has been corelated with
poor prognosis in OC [18]. Increased transcription of several
extracellular proteases by ETS1 has been shown to promote in-
vasion in ovarian cancer [13,44]. Our studies for the first time
report the increased expression of ETS1 in the metastasizing OC
cells upon productive interactions with themicroenvironment of
the metastatic site. It further revealed that this microenviron-
ment induced increase in ETS1 played a significant role in met-
astatic colonization.
Our approach of a combination of RNA-seq of ETS1 silenced
OC cells and ChIP-seq revealed its direct targets in ovarian cancer
(Fig. 4). PTK2which codes for FAKwas identified as a novel target
regulated by ETS1. Upon attaching to the omentum, the metas-
tasizing OC cells need to invade through the mesothelium and
the underlying basement membrane in order to subsequently
establish the metastatic colonies. FAK is known to be a key
promoter of invasion and interactions with the ECMs present in
the basement membrane [10,45]. Therefore, we decided to focus
on PTK2 among the top targets of ETS1. While ETS1 has been
reported to promote breast cancer metastasis through b1-
integrin mediated FAK/SRC/AKT signaling [46], we are the first to
report PTK2 as a direct transcriptional target of ETS1. FAK has
been previously demonstrated to play an important role in
ovarian cancer metastasis as a downstream signaling pathway
induced by a5b1-integrinwhen the metastsizing OC cells interact
with fibronectin secreted by mesothelial cells [10,35]. Similarly,
sufficient activation of FAK is deemed essential for successful
metastatic colonization of breast cancer cells in the lungs [32]. It
has been reported as a potential theraputic target in severalcancers [47e49]. The OC cells attempting to colonize the meta-
static site need to initially invade through the mesothelium and
potentially through the basement membrane. An increased
expression of FAK can facilitate this process and is key to suc-
cessful colonization. Overexpression of FAK rescued the reduced
migration in ETS1 KO cells (Fig. 5D) which demonstrated that
FAK is a functional mediator of ETS1 during OC metastasis. This
reveals a novel mechanism of increased expression of FAK as a
result of ETS1 induction by the microenvironment. The increased
amounts of FAK can be activated by the integrin mediated
signaling triggered by the OC cells invading through the ECM of
the basment membrane of the omentum during early metastatic
colonization [10,47].
Our data demonstrated that the interaction of the OC cells
with themesothelial cells activatedMAPK signaling, which led to
the upregulation of ETS1. This agrees with the reported mecha-
nism of ETS1 activation by MAPK signaling which increases its
own transcription [25]. MAPK signaling is activated in metastatic
serous OC and is reported to promote metastasis [50,51]. It has
been shown to be activated in the metastasizing OC cells and
other cancer cells by TGFb, which is abundantly present in the
metastatic microenvironment [39,52e54]. These can be poten-
tial mechanism of the cross-talk of the cancer cells with the
mesothelium. However, this is the first report of an induction of
ETS1 by MAPK activation through productive interactions with
the metastatic microenviroment, which is an important mech-
anism to allow OC cells to establish metastases. Of note, our
study accesses the role of the microenvironment in the initial
steps of colonization and future studies need to focus on sub-
sequent critical steps including induction of angiogenesis and
metabolic reprogramming and the effects of hypoxia as the
metastatic tumor grows in size. Similarly, the role of other ETS1
targets and their potential combanitorial effects on metastasis
need to be studied in the future.
It is well documented that metastatic colonization is the rate
limiting step of metastasis [8]. Disrupting the adaptive responses
induced in the metastatic OC cells through their productive in-
teractions with the omental microenvironment is a potentially
promising approach to treat metastatic disease. This approach
can probably prevent reseeding of metastatic tumors or devel-
opment of the residual micrometastasis into full blown meta-
static tumors post debulking surgery. Therefore, targeting this
pathway could potentially reduce metastatic colonization by
preventing induction of ETS1. A viable alternative approach for
treating metastatic OC would be to target FAK, one of the key
functional mediators of ETS1.
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